Literature DB >> 24224811

Kinetic mechanisms of mutation-dependent Harvey Ras activation and their relevance for the development of Costello syndrome.

Michael Wey1, Jungwoon Lee, Soon Seog Jeong, Jungho Kim, Jongyun Heo.   

Abstract

Costello syndrome is linked to activating mutations of a residue in the p-loop or the NKCD/SAK motifs of Harvey Ras (HRas). More than 10 HRas mutants that induce Costello syndrome have been identified; G12S HRas is the most prevalent of these. However, certain HRas p-loop mutations also are linked to cancer formation that are exemplified with G12V HRas. Despite these relations, specific links between types of HRas mutations and diseases evade definition because some Costello syndrome HRas p-loop mutations, such as G12S HRas, also often cause cancer. This study established novel kinetic parameter-based equations that estimate the value of the cellular fractions of the GTP-bound active form of HRas mutant proteins. Such calculations differentiate between two basic kinetic mechanisms that populate the GTP-bound form of Ras in cells. (i) The increase in the level of GTP-bound Ras is caused by the HRas mutation-mediated perturbation of the intrinsic kinetic characteristics of Ras. This generates a broad spectrum of the population of the GTP-bound form of HRas that typically causes Costello syndrome. The upper end of this spectrum of HRas mutants, as exemplified by G12S HRas, can also cause cancer. (ii) The increase in the level of GTP-bound Ras occurs because the HRas mutations perturb the action of p120GAP on Ras. This causes production of a significantly high population of the only GTP-bound form of HRas linked merely to cancer formation. HRas mutant G12V belongs to this category.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24224811      PMCID: PMC3918454          DOI: 10.1021/bi400679q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  55 in total

1.  GEFs: master regulators of G-protein activation.

Authors:  S Sprang
Journal:  Trends Biochem Sci       Date:  2001-04       Impact factor: 13.807

2.  HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation.

Authors:  Karen W Gripp; Angela E Lin; Deborah L Stabley; Linda Nicholson; Charles I Scott; Daniel Doyle; Yoko Aoki; Yoichi Matsubara; Elaine H Zackai; Pablo Lapunzina; Antonio Gonzalez-Meneses; Jennifer Holbrook; Cynthia A Agresta; Iris L Gonzalez; Katia Sol-Church
Journal:  Am J Med Genet A       Date:  2006-01-01       Impact factor: 2.802

3.  The Son of sevenless gene product: a putative activator of Ras.

Authors:  L Bonfini; C A Karlovich; C Dasgupta; U Banerjee
Journal:  Science       Date:  1992-01-31       Impact factor: 47.728

Review 4.  Hyperactive Ras in developmental disorders and cancer.

Authors:  Suzanne Schubbert; Kevin Shannon; Gideon Bollag
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

5.  Differential Regulation of RasGAPs in Cancer.

Authors:  Thomas Grewal; Meryem Koese; Francesc Tebar; Carlos Enrich
Journal:  Genes Cancer       Date:  2011-03

6.  Differential regulation of rasGAP and neurofibromatosis gene product activities.

Authors:  G Bollag; F McCormick
Journal:  Nature       Date:  1991-06-13       Impact factor: 49.962

7.  Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation.

Authors:  Ellen Denayer; Annabel Parret; Magdalena Chmara; Suzanne Schubbert; Annick Vogels; Koen Devriendt; Jean-Pierre Frijns; Vladimir Rybin; Thomy J de Ravel; Kevin Shannon; Jan Cools; Klaus Scheffzek; Eric Legius
Journal:  Hum Mutat       Date:  2008-02       Impact factor: 4.878

8.  Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.

Authors:  A L Schulz; B Albrecht; C Arici; I van der Burgt; A Buske; G Gillessen-Kaesbach; R Heller; D Horn; C A Hübner; G C Korenke; R König; W Kress; G Krüger; P Meinecke; J Mücke; B Plecko; E Rossier; A Schinzel; A Schulze; E Seemanova; H Seidel; S Spranger; B Tuysuz; S Uhrig; D Wieczorek; K Kutsche; M Zenker
Journal:  Clin Genet       Date:  2007-11-27       Impact factor: 4.438

9.  Costello syndrome associated with novel germline HRAS mutations: an attenuated phenotype?

Authors:  Karen W Gripp; A Micheil Innes; Marni E Axelrad; Tanya L Gillan; Jillian S Parboosingh; Christine Davies; Norma J Leonard; Monique Lapointe; Daniel Doyle; Sarah Catalano; Linda Nicholson; Deborah L Stabley; Katia Sol-Church
Journal:  Am J Med Genet A       Date:  2008-03-15       Impact factor: 2.802

10.  Membrane-dependent signal integration by the Ras activator Son of sevenless.

Authors:  Jodi Gureasko; William J Galush; Sean Boykevisch; Holger Sondermann; Dafna Bar-Sagi; Jay T Groves; John Kuriyan
Journal:  Nat Struct Mol Biol       Date:  2008-05-04       Impact factor: 15.369

View more
  14 in total

Review 1.  Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.

Authors:  Dongsung Kim; Jenny Yaohua Xue; Piro Lito
Journal:  Cell       Date:  2020-10-15       Impact factor: 41.582

2.  Development of Noonan syndrome by deregulation of allosteric SOS autoactivation.

Authors:  Hope Gloria Umutesi; Hanh My Hoang; Hope Elizabeth Johnson; Kwangho Nam; Jongyun Heo
Journal:  J Biol Chem       Date:  2020-08-04       Impact factor: 5.157

Review 3.  New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling.

Authors:  Keesha E Erickson; Oleksii S Rukhlenko; Richard G Posner; William S Hlavacek; Boris N Kholodenko
Journal:  Semin Cancer Biol       Date:  2018-03-05       Impact factor: 15.707

4.  Genotype and phenotype spectrum of NRAS germline variants.

Authors:  Franziska Altmüller; Christina Lissewski; Debora Bertola; Elisabetta Flex; Zornitza Stark; Stephanie Spranger; Gareth Baynam; Michelle Buscarilli; Sarah Dyack; Jane Gillis; Helger G Yntema; Francesca Pantaleoni; Rosa LE van Loon; Sara MacKay; Kym Mina; Ina Schanze; Tiong Yang Tan; Maie Walsh; Susan M White; Marena R Niewisch; Sixto García-Miñaúr; Diego Plaza; Mohammad Reza Ahmadian; Hélène Cavé; Marco Tartaglia; Martin Zenker
Journal:  Eur J Hum Genet       Date:  2017-05-03       Impact factor: 4.246

Review 5.  The renewed battle against RAS-mutant cancers.

Authors:  Fuquan Zhang; Jit Kong Cheong
Journal:  Cell Mol Life Sci       Date:  2016-02-18       Impact factor: 9.261

6.  Intrinsic GTPase Activity of K-RAS Monitored by Native Mass Spectrometry.

Authors:  Zahra Moghadamchargari; Jamison Huddleston; Mehdi Shirzadeh; Xueyun Zheng; David E Clemmer; Frank M Raushel; David H Russell; Arthur Laganowsky
Journal:  Biochemistry       Date:  2019-07-22       Impact factor: 3.162

7.  Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S).

Authors:  Ziyang Zhang; Keelan Z Guiley; Kevan M Shokat
Journal:  Nat Chem Biol       Date:  2022-07-21       Impact factor: 16.174

8.  Mechanisms underlying cognitive deficits in a mouse model for Costello Syndrome are distinct from other RASopathy mouse models.

Authors:  Jadwiga Schreiber; Laura-Anne Grimbergen; Iris Overwater; Thijs van der Vaart; Jeffrey Stedehouder; Alberto J Schuhmacher; Carmen Guerra; Steven A Kushner; Dick Jaarsma; Ype Elgersma
Journal:  Sci Rep       Date:  2017-04-28       Impact factor: 4.379

9.  Structural impact of GTP binding on downstream KRAS signaling.

Authors:  Dóra K Menyhárd; Gyula Pálfy; Zoltán Orgován; István Vida; György M Keserű; András Perczel
Journal:  Chem Sci       Date:  2020-08-19       Impact factor: 9.825

10.  Superoxide inhibits guanine nucleotide exchange factor (GEF) action on Ras, but not on Rho, through desensitization of Ras to GEF.

Authors:  Michael Wey; Vinh Phan; Gerardo Yepez; Jongyun Heo
Journal:  Biochemistry       Date:  2014-01-14       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.